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Objectives: Arterial stiffness is recognized as an independent risk factor for cardiovascular morbidity and
mortality. Recent studies found that osteoprotegerin (OPG) is associated with arterial stiffness and may
reﬂect endothelial dysfunction. The aim of this study was to evaluate the relationship between fasting
serum OPG levels and the aortic augmentation index (AIx) in renal transplant recipients.
Materials and methods: Fasting blood samples were obtained from 66 renal transplant recipients. The
aortic AIx was measured using a validated tonometry system (SphygmoCor). Serum OPG levels were
measured using a commercial enzyme-linked immunosorbent assay kit.
Results: Univariate linear analysis of the aortic AIx in renal transplant recipients revealed that body fat
mass (r ¼ 0.377, p ¼ 0.002), aortic diastolic blood pressure (DBP; r ¼ 0.307, p ¼ 0.020), triglycerides
(r ¼ 0.260, p ¼ 0.035), and logarithmically transformed OPG (log-OPG, r ¼ 0.402, p < 0.001) were
positively correlated, whereas height (r ¼ 0.361, p ¼ 0.004) and body weight (r ¼ 0.212, p ¼ 0.041) were
negatively correlated with the aortic AIx in renal transplant recipients. Multivariate forward stepwise
linear regression analysis of the factors signiﬁcantly associated with the aortic AIx showed that log-OPG
(R2 ¼ 0.213, p < 0.001), height (R2 ¼ 0.081, p ¼ 0.009), and aortic DBP (R2 ¼ 0.058, p ¼ 0.022) were
independent predictors of the aortic AIx in renal transplant recipients.
Conclusion: These results suggest that the serum fasting OPG level is associated with the aortic AIx in
renal transplant recipients.
Copyright © 2016, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Cardiovascular (CV) disease is still a major cause of mortality in
renal transplant recipients. This is partially attributed to nonclassic
CV disease risk factors including arterial stiffness, an established
independent predictor of mortality in several patient populations
[1]. The European Society of Cardiology Working Group described
the importance of peripheral noninvasive vascular biomarkers forddhist Tzu Chi General Hos-
wan. Tel.: þ886 3 8561825;
ee).
lief Tzu Chi Foundation. Publishedprimary and secondary CV disease prevention [2]. Among them,
noninvasive methods to assess central hemodynamics/wave re-
ﬂections such as the aortic augmentation index (AIx) of central
blood pressure have been widely used as clinical indices of arterial
stiffness [2,3]. The AIx (augmentation pressure-to-pulse pressure
ratio) is ameasure of the contribution that wave reﬂectionmakes to
the central pressure wave: it is deﬁned as the difference between
the second and ﬁrst peaks corresponding to the systolic blood
pressure (SBP) and expressed as a percentage of the pulse pressure.
Thus, the AIx is an indirect measure of central arterial stiffness, but
mainly a direct measure of central wave reﬂection [4].
Vascular calciﬁcation is a tightly controlled process similar to
bone formation, wheremineralization of the internal elastic lamina
and elastic ﬁbers in the media results in vascular stiffening [5e7].by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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itor. It can prevent vascular calciﬁcation by blocking the bone
remodeling process in vascular tissue and by neutralizing the
proapoptotic actions of tumor necrosis factorerelated apoptosis-
inducing ligand [6]. Elevated serum OPG is an independent pre-
dictor of death from any cause or of CV death among renal trans-
plant recipients [8]. In the Assessment of Lescol in Renal
Transplantation study, elevated serum OPG level was also found to
be independently associated with renal events, CV events, and
mortality in renal transplant recipients [9]. Our previous studies
noted that high OPG levels were associated with central arterial
stiffness measured by carotidefemoral pulse wave velocity in hy-
pertensive patients and renal transplant recipients [10,11]. The aim
of this study was to determine the relationship between fasting
serum OPG levels and arterial stiffness, as measured by the aortic
AIx, in renal transplant recipients.
2. Materials and methods
2.1. Patients
Between May and August 2013, 66 renal transplant recipients
from a medical center in Hualien, Taiwan, were enrolled in this
study. The Human Subjects Institutional Review Board of Tzu Chi
University and General Hospital approved this study. Patients were
excluded if they had any acute infection, malignancy, acute rejec-
tion, acute myocardial infarction, or pulmonary edema at the time
of blood sampling as well as if they had an arterialevenous shunt or
had received a graft in the hands. Patients using medications
related to calcium, active vitamin D metabolites, bisphosphonates,
teriparatide, or estrogen were excluded as were those who refused
to provide informed consent.
2.2. Anthropometric analysis
The participants' weights were measured in light clothing and
without shoes to the nearest 0.5 kg, and their height was measured
to the nearest 0.5 cm. Bodymass indexwas calculated as theweight
in kilogram divided by the height in meter square [10e12]. Bio-
impedance measurements of fat mass were performed at the
bedside according to the standard tetrapolar whole-body (hand-
foot) technique, using a single-frequency (50 kHz) analyzer
(Biodynamic-450, Biodynamics Corporation, Seattle, WA, USA).
Measurements were carried out by the same operator for all
patients.
2.3. Biochemical investigations
Fasting blood samples (approx. 5 mL collected) of approxi-
mately 0.5 mL for hemoglobin and white blood cell counts
(Sysmex K-1000, Sysmex American, Mundelein, IL, USA) were
immediately centrifuged at 3000g for 10 minutes. Serum levels of
blood urea nitrogen (BUN), creatinine (Cre), fasting glucose, total
cholesterol, triglycerides (TGs), high-density lipoprotein-choles-
terol, low-density lipoprotein-cholesterol, total calcium, and
phosphorus were measured using an autoanalyzer (cobas integra
800, Roche Diagnostics, Basel, Switzerland) [10e12]. Serum OPG
levels (eBioscience Inc., San Diego, CA, USA) were measured us-
ing a commercially available enzyme-linked immunosorbent
assay (ELISA) [10e12]. The limit of detection calculated as the
concentration of human OPG corresponding to the blank average
minus three standard deviations was 2.5 pg/mL. The inter- and
intra-assay coefﬁcients of variation for OPG were 8.0% and 7.0%,
respectively. The participants' serum intact parathyroid hormone
(iPTH; Diagnostic Systems Laboratories, Webster, TX, USA) levelswere measured using a commercially available ELISA [10e12].
The equation from the Modiﬁcation of Diet in Renal Disease was
used to calculate the estimated glomerular ﬁltration rate in this
study.2.4. Pulse wave analysis and aortic AIx assessment
Patients were positioned supine and allowed to rest for 10 mi-
nutes prior to the test. Consumption of food, drink, alcohol, and
tobacco was not restricted, but patients were not allowed to sleep
or talk during the testing procedure. Pulse wave analysis was per-
formed by applanation tonometry on the right radial artery and
analyzed by SphygmoCor software (SphygmoCor system, AtCor
Medical, West Ryde, Australia) [10,11]. This software calculates a
number of major indices including the aortic AIx aortic SBP, and
aortic diastolic blood pressure (DBP). Pulse pressure was calculated
by subtracting the DBP from the SBP.2.5. Statistical analysis
Data were tested for normal distribution using the Kolmogor-
oveSmirnov test. Data were expressed as means ± standard devi-
ation for normally distributed data and as medians and
interquartile ranges for non-normally distributed data. The glucose,
BUN, Cre, iPTH, and OPG datasets showed skewed non-normal
distributions, and therefore, were recalculated by transformation
to the logarithm base 10; after this transformation, the log-glucose,
log-BUN, log-Cre, log-iPTH, and log-OPGwere normally distributed.
Clinical variables that correlated with the aortic AIx values in renal
transplant recipients were ﬁrst evaluated by univariate linear
regression analysis. Variables that were signiﬁcantly associated
with the aortic AIx in the renal transplant recipients were tested for
independence by multivariate forward stepwise regression anal-
ysis. All data were analyzed using SPSS for Windows (version 19.0;
SPSS Inc., Chicago, IL, USA). A p value of less than 0.05 was
considered statistically signiﬁcant.3. Results
The clinical and laboratory anthropometric and biochemical
data of the 66 renal transplant recipients are presented in Table 1.
Table 2 shows that 40 patients had diabetes (60.6%) and 17 had
hypertension (25.8%). The immunological medications prescribed
to the renal transplant recipients included tacrolimus (n ¼ 38,
57.6%), mycophenolate mofetil or mycophenolic acid (n ¼ 49,
74.2%), steroids (n ¼ 54, 81.8%), rapamycin (n ¼ 11, 16.7%), and
cyclosporine (n ¼ 17, 25.8%). There were no statistically signiﬁcant
differences in aortic AIx values based on sex, transplantation
model, diabetes, hypertension, or use of the immunological medi-
cations listed.
Univariate linear analysis of the aortic AIx values of the 66 renal
transplant recipients is presented in Table 3. Body fat mass
(r ¼ 0.377, p ¼ 0.002), aortic DBP (r ¼ 0.307, p ¼ 0.020), TGs
(r ¼ 0.260, p ¼ 0.035), and log-OPG (r ¼ 0.402, p < 0.001) were
positively correlated, whereas height (r ¼ 0.361, p ¼ 0.004) and
body weight (r ¼ 0.212, p ¼ 0.041) were negatively correlated with
the aortic AIx in these patients.
Multivariate forward stepwise linear regression analysis of the
variables that were signiﬁcantly associated with the aortic AIx
levels in univariate analysis showed that log-OPG (b ¼ 0.397,
R2 ¼ 0.213, p < 0.001), height (b ¼ 0.260, R2 ¼ 0.081, p ¼ 0.009),
and aortic DBP (b¼ 0.243, R2¼ 0.058, p¼ 0.022) were independent
predictors of the aortic AIx in these patients (Table 4).
Table 1
Clinical and analytical characteristics of the 66 renal transplant recipients.
Items Parameter
Anthropometric data Age (years) 51.59 ± 9.32
KT duration (months) 71.30 ± 43.55
Height (cm) 162.32 ± 8.36
Body weight (kg) 62.36 ± 12.65
Body mass index (kg/m2) 23.78 ± 4.19
Waist circumference (cm) 84.88 ± 11.20
Body fat mass (%) 29.06 ± 6.39
Aortic SBP (mmHg) 139.48 ± 16.51
Aortic DBP (mmHg) 87.24 ± 10.57
Pulse pressure (mmHg) 52.24 ± 12.69
Augmentation index (%) 18.17 ± 11.09
Biochemical data White blood count (1000/mL) 7.02 ± 2.46
Hemoglobin (g/dL) 12.32 ± 2.29
Total cholesterol (mg/dL) 195.94 ± 46.83
Triglyceride (mg/dL) 144.13 ± 108.62
HDL-C (mg/dL) 52.27 ± 16.42
LDL-C (mg/dL) 106.60 ± 34.45
Fasting glucose (mg/dL) 94.50 (86.00e110.00)
Blood urea nitrogen (mg/dL) 22.00 (17.00e34.25)
Creatinine (mg/dL) 1.50 (1.18e2.03)
GFR (ml/min) 43.38 ± 21.49
Total Calcium (mg/dL) 9.21 ± 1.06
Phosphorus (mg/dL) 3.36 ± 0.80
Calcium-phosphorous product 30.61 ± 6.46
iPTH (pg/mL) 115.75 (70.80e155.65)
Osteoprotegerin (pg/L) 3.20 (1.27e9.57)
Values for continuous variables given as means ± standard deviation and variables
not normally distributed given as medians and interquartile range.
DBP ¼ diastolic blood pressure; GFR ¼ glomerular ﬁltration rate; HDL-C ¼ high-
density lipoprotein-cholesterol; iPTH ¼ intact parathyroid hormone; KT ¼ kidney
transplantation; LDL-C ¼ low-density lipoprotein-cholesterol; SBP ¼ systolic blood
pressure.
Table 3
Correlation of aortic augmentation index levels and clinical variables by univariate
linear regression analysis among the 66 renal transplant recipients.
Variable r p
Age (y) 0.021 0.868
Kidney transplantation duration (mo) 0.093 0.456
Height (cm) 0.361 0.003 *
Body weight (kg) 0.252 0.041 *
Body mass index (kg/m2) 0.155 0.215
Body fat mass (%) 0.377 0.002 *
Aortic systolic blood pressure (mmHg) 0.160 0.200
Aortic diastolic blood pressure (mmHg) 0.307 0.020 *
Pulse pressure (mmHg) 0.048 0.704
White blood count ( 1000/mL) 0.002 0.987
Hemoglobin (g/dL) 0.144 0.247
Total cholesterol (mg/dL) 0.157 0.209
Triglyceride (mg/dL) 0.260 0.035 *
HDL-C (mg/dL) 0.049 0.698
LDL-C (mg/dL) 0.035 0.781
Log-glucose (mg/dL) 0.014 0.912
Log-blood urea nitrogen (mg/dL) 0.141 0.260
Log-creatinine (mg/dL) 0.006 0.962
Glomerular ﬁltration rate (mL/min) 0.239 0.054
Total calcium (mg/dL) 0.115 0.356
Phosphorus (mg/dL) 0.175 0.160
Ca  P product (mg2/dL2) 0.118 0.347
Log-osteoprotegerin (pg/L) 0.462 <0.001 *
Log-intact parathyroid hormone (pg/mL) 0.008 0.950
* p < 0.05 is considered statistically signiﬁcant in the univariate linear analyses.
HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density lipoprotein-
cholesterol.
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The current results reveal that body fat mass, aortic DBP, TGs,
and log-OPG were positively correlated, whereas height and body
weight were negatively correlated with the aortic AIx in renalTable 2
Clinical characteristics and aortic augmentation index levels of the 66 renal trans-
plant recipients.
Characteristic n (%) Augmentation index (%) p
Sex
Male 36 (54.5) 15.57 ± 11.20 0.052
Female 30 (45.5) 21.07 ± 10.41
Diabetes
No 26 (39.4) 15.31 ± 9.44 0.091
Yes 40 (60.6) 20.03 ± 11.78
Hypertension
No 49 (74.2) 17.88 ± 11.49 0.722
Yes 17 (25.8) 19.00 ± 10.13
Transplantation model
Cadaveric 57 (86.4) 17.44 ± 11.47 0.182
Living 9 (13.6) 22.78 ± 7.07
Tacrolimus use
No 28 (42.4) 17.18 ± 10.06 0.538
Yes 38 (57.6) 18.89 ± 11.87
Mycophenolate mofetil or mycophenolic acid use
No 17 (25.8) 19.65 ± 12.14 0.527
Yes 49 (74.2) 17.65 ± 10.79
Steroid use
No 12 (18.2) 19.92 ± 12.47 0.550
Yes 54 (81.8) 17.78 ± 10.85
Rapamycin use
No 55 (83.3) 18.31 ± 11.28 0.818
Yes 11 (16.7) 17.45 ± 10.58
Cyclosporine use
No 49 (74.2) 18.53 ± 11.52 0.654
Yes 17 (25.8) 17.12 ± 9.99
* p < 0.05 was considered statistically signiﬁcant after the Student independent t
test.transplant recipients in univariate analysis. After adjusting these
signiﬁcant variables using multivariate forward stepwise linear
regression analysis, log-OPG, height, and aortic DBP were identiﬁed
as independent predictors of aortic AIx values in renal transplant
recipients. A high serum OPG level was associated with the aortic
AIx in renal transplant recipients.
Aortic stiffness increases central systolic pressure (increased
cardiac load and oxygen consumption), lowers diastolic pressure
(decreased myocardial perfusion pressure), and promotes degen-
eration of the elastic components of the arterial wall. The net result
is an imbalance toward myocardial ischemia and an impairment of
left ventricular function [2]. Aortic stiffness is a strong predictor of
future CV events and all-cause mortality in humans [13]. In addi-
tion, aortic stiffness is also a strong predictor of future CV events in
renal transplant recipients [14]. In a meta-analysis of 5648 patients,
the aortic AIx was an independent predictor of CV events; of in-
terest, it also independently predicted all-cause mortality [15].
Aging of the arterial system is accompanied by progressive struc-
tural changes, involving fragmentation and degeneration of elastin,
increases in collagen, thickening of the arterial wall, endothelium
damage, and progressive dilation of the arteries [16]. The aortic AIx
was signiﬁcantly higher in women than in men and the increase in
AIx with age was curvilinear in a population study based on 4561
participants from the Copenhagen City Heart Study in Denmark
[17]. The same group also noted that the aortic AIx directlyTable 4
Multivariate stepwise linear regression analysis of body fat mass, aortic diastolic
blood pressure, triglyceride, height, body weight, and log-OPG: correlation with
aortic augmentation index levels among 66 renal transplant recipients.
Variable Beta R2 R2 change p
Log-osteoprotegerin (pg/L) 0.397 0.213 0.213 <0.001 *
Height (cm) 0.260 0.294 0.081 0.009 *
Aortic diastolic blood pressure (mmHg) 0.243 0.352 0.058 0.022 *
* p < 0.05 is considered statistically signiﬁcant in the multivariate stepwise linear
regression analysis.
OPG ¼ osteoprotegerin.
B.-G. Hsu et al. / Tzu Chi Medical Journal 28 (2016) 20e23 23increased with height and SBP in a study based on 3432 partici-
pants [18]. However, a recent study noted that age and SBP were
not signiﬁcantly associated with the aortic Aix in renal transplant
recipients [19]. The aortic AIx was inversely associated with height
in a study on randomly selected community-dwelling adults
(N ¼ 1152) [20]. In normal-weight individuals, it was signiﬁcantly
higher in those with metabolic syndrome than in those without the
syndrome [21]. Weight loss on a 12-week training program was
signiﬁcantly and independently associated with reduction in AIx
values after adjustment for heart rate at 75 beats per minute among
Japanese elderly persons [22]. Our study showed that body fat
mass, aortic DBP, and TGs were positively correlated, whereas
height and body weight were negatively correlated with aortic AIx
in renal transplant recipients. However, our study did not ﬁnd a
statistically signiﬁcant association between aortic AIx values and
age in renal transplant recipients. There is a tendency for female
renal transplant recipients to have higher aortic AIx values than
men, but it just missed statistical signiﬁcance in our study
(p ¼ 0.052). Aortic DBP was positively associated with aortic AIx,
whereas height was negatively associated with aortic AIx values
among renal transplant recipients in our study after multivariable
analysis.
OPG is a vascular calciﬁcation inhibitor that strongly inhibits
bone resorption [6]. Vascular calciﬁcation is an active, complex
process that involves numerous mechanisms responsible for
calcium deposition in the arterial walls, leading to an increase in
arterial stiffness [7,23]. Clinical studies have suggested that an
increase in serum OPG levels is associated with renal events, CV
events, and mortality in renal transplant recipients [8,9]. A high
level of OPG has been signiﬁcantly associated with the progres-
sion of abdominal aortic calciﬁcation in renal transplant re-
cipients [24]. The serum OPG level was also positively associated
with AIx values in postmenopausal women with osteoporosis
[25]. Our study showed that serum log-OPG concentrations were
positively correlated with aortic AIx values in renal transplant
recipients. This relationship remained signiﬁcant even after
adjustment for several confounders affecting renal transplant
recipients.
Our study had some limitations. First, the number of patients
enrolled was small, thereby weakening the statistical power of the
results. Second, antihypertensive drugs such as b-blockers increase
the aortic AIx by decreasing central to brachial ampliﬁcation [26].
We did not record antihypertension regimens in this study. Further
studies are needed to elucidate the causal relationship between
serumOPG levels andaorticAIx values in renal transplant recipients.
In conclusion, this study showed positive associations between
AIx values and log-OPG and aortic DBP, and a negative association
between AIx values and height in renal transplant recipients. We
feel further studies and investigations are needed to understand
the effects of these factors on AIx values in renal transplant
recipients.
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